Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10367950" target="_blank" >RIV/00216208:11110/18:10367950 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/18:00102719 RIV/00209805:_____/18:00077997 RIV/00216208:11130/18:10367950 RIV/00216208:11140/18:10367950 and 6 more
Result on the web
<a href="http://dx.doi.org/10.21873/anticanres.12243" target="_blank" >http://dx.doi.org/10.21873/anticanres.12243</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.12243" target="_blank" >10.21873/anticanres.12243</a>
Alternative languages
Result language
angličtina
Original language name
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
Original language description
Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Volume of the periodical
38
Issue of the periodical within the volume
1
Country of publishing house
GR - GREECE
Number of pages
8
Pages from-to
449-456
UT code for WoS article
000419130100060
EID of the result in the Scopus database
2-s2.0-85039776678